The test will be distributed by Infrawear to labs and pharmacies in the United Kingdom, France, Italy, Germany and elsewhere in the EU.
It was also just announced that Genesprint and Infrawear just made it to the semi-finals for the USD 5m XPRIZE Rapid COVID Testing competition. The test has been CE marked to the IVD Directive (98/79/EC).
Genesprint Group Ltd has been developing research and manufacturing diagnostic kits for various infectious diseases for more than three years.
The virology team has 50 years of combined rapid test development experience. It has been working on COVID-19 tests since the virus first appeared.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial